Dosing & Uses
Dosage Forms & Strengths
capsule
- 5mg
tablet
- 5mg
solution (iv)
- 0.4mg/mL (10mL)
Dietary Supplement
2-5 mg PO qDay or more; not to exceed 8 mg/day
Alternatively (parenteral nutrition): 0.3-0.5 mg/day IV or 0.5-1.5 mg/day IV (per manufacturer)
High Output Fistula
- May use twice the recommended daily allowance
RDA
- Males: 900 mcg/day
- Females: 900 mcg/day
- Pregnant: 1,000 mcg/day
- Nursing: 1,300 mcg/day
- UL (>19 years old): 10,000 mcg/day
Keratoconus (Orphan)
Orphan designation for treatment of keratoconus
Sponsor
- iVeena Drug Delivery Systems, Inc; 391 Chipeta Way, Suite I; Salt Lake City, Utah 84108
Dosage Forms & Strengths
capsule
- 5mg
tablet
- 5mg
solution (iv)
- 0.4mg/mL (10mL)
Dietary Supplement
Parenteral nutrition: 20 mcg copper/kg/day IV
RDA
- 0-6 months old: 200 mcg/day
- 7-12 months old: 220 mcg/day
- 1-3 years old: 340 mcg/day
- 3-8 years old: 440 mcg/day
- 8-13 years old: 700 mcg/day
- 13-18 years old: (Male, Female) 890 mcg/day
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (1)
- baloxavir marboxil
copper will decrease the level or effect of baloxavir marboxil by cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted.
Monitor Closely (3)
- omadacycline
copper will decrease the level or effect of omadacycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.
- penicillamine
copper decreases effects of penicillamine by pharmacodynamic antagonism. Use Caution/Monitor.
- sarecycline
copper will decrease the level or effect of sarecycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.
Minor (3)
- ascorbic acid
ascorbic acid decreases levels of copper by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- rose hips
rose hips decreases levels of copper by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- trientine
trientine decreases levels of copper by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Indicated action (for Wilson's disease).
Adverse Effects
Frequency Not Defined
Nausea/vomiting (10-60 mg dose)
Hepatic dysfunction including necrosis
Warnings
Contraindications
None listed by manufacturer
Cautions
Administration not recommended in Wilson disease
Use caution in patients with hepatic impairment
Injection contains aluminum; use caution in renal impairment and premature infants
Acidic pH of the solution may cause tissue irritation
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Excretion in milk unknown; use with caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Cofactor in many enzymes, including ceruloplasmin; involved in formation of iron carrier protein, transferrin
Helps maintain normal rates of red and white blood cell formation and helps prevent development of deficiency symptoms
Pharmacokinetics
Excretion: Intestinal wall, urine, and bile
Administration
Not for direct administration; must dilute; administer only after dilution in not less than 100 mL
No preservatives - use promptly & discard unused portion
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.